In a bold strategic move, Ever Supreme Bio Technology Co., Ltd. announced a NT$1.7 billion all-share acquisition of Shine Out Biotechnology Co., Ltd., aiming to accelerate its position in exosome therapeutics and cell-based drug innovation.
 
This acquisition unlocks new value across oncology, neurodegeneration, and advanced drug delivery, positioning Ever Supreme as a key regional player in the rapidly expanding exosome and regenerative medicine market.
 

• 100% share-swap acquisition, completion expected Jan 2026
• Shine Out adds proprietary dopamine transporter (dEV) and integrin exosome (iEV) platforms
• Dual Pre-IND programs launching by year-end, with global IP coverage
• Strategic integration of Shine Out’s R&D with Ever Supreme’s GMP manufacturing strength for faster clinical and commercial scale-up

 
Learn how Ever Supreme is reshaping Taiwan’s biotech landscape:
https://reurl.cc/GN0o7D